Propanc Biopharma, Inc. (PPCB)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Propanc Biopharma Enables Hexstone Resale After $1M Deal
# 📄 What This Document Is This is an **S-1 registration statement** filed with the SEC. It's not for a brand-new IPO. Instead, it's a "resale registration" for an investor, **Hexstone Capital LLC**, who bought special stock from the company. This filing allows Hexstone to later sell the shares they
SEC filings
All filings →Insider trades
All insider trades →Propanc Biopharma, Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Propanc Biopharma, Inc.
All people →No officers or directors have been indexed for Propanc Biopharma, Inc..